CHALK RIVER, Ontario, Nov. 25, 2021 (GLOBE NEWSWIRE) — Canadian Nuclear Laboratories (CNL), Canada’s premier nuclear science and expertise group, is happy to announce that it has issued a name for proposals for a brand new ‘health stream’ inside its Canadian Nuclear Research Initiative (CNRI). The new program is designed to speed up the improvement of focused radiopharmaceuticals in Canada via collaborative analysis initiatives associated to well being sciences, radiobiology and medical isotope improvement, by offering entry to the world-class laboratories and analysis capabilities at the Chalk River Laboratories campus.

Launched in 2019, the CNRI program was initially established by CNL to advance the deployment of small modular reactor (SMRs) and superior reactor designs. The ongoing curiosity in the program has led CNL to increase CNRI into well being sciences, one other key space of experience, permitting members to achieve entry to the firm’s distinctive services and personnel so as to conduct analysis in partnership with CNL.

“With over one billion medical treatments conducted using isotopes produced at the Chalk River Laboratories, CNL’s work has touched the lives of people all around the world,” commented Joe McBrearty, CNL’s President and CEO. “Today, we continue to pursue this mission as a full-service nuclear laboratory with the capability to perform cutting-edge pharmaceutical development, along with a wide range of radiochemical analyses. Through the expanded CNRI program, we hope to better leverage our resources to help people who suffer from a wide range of medical issues, with a key focus on cancer treatment.”

For the program’s first consumption, analysis proposals should align with subjects that embody focused supply techniques, toxicology and pre-clinical analysis. Once a technical overview of every proposal is accomplished, CNL will work with the proponent to develop a plan to set up the scope, funds, and deliverables for the undertaking. CNL will full a last analysis of the proposed undertaking plans earlier than making the last choice and approval of profitable candidates. The deadline for submissions is January 15, 2022, and initiatives might be chosen in the spring of 2022.

As a world chief in medical isotopes and associated analysis for greater than 70 years, CNL has helped pioneer the use of Cobalt-60 radiation remedy for the therapy of most cancers, and served as a serious producer of the world’s provide of Molybdenum-99, which is utilized in diagnostic procedures. CNL now maintains various capabilities in areas of well being and dosimetry, together with pre-clinical animal research, isotope manufacturing and processing, in vitro drug analysis, focused radionuclide therapies, ISO-accredited analytical chemistry providers and waste administration options.

“The CNRI program has been incredibly successful for the development of SMRs and other advanced reactor technologies, and it encouraged us to apply this collaborative model to other areas of our research,” commented Dr. Jeff Griffin, CNL’s Vice-President of Science & Technology. “We believe there is an unmet need for organizations that are pursuing radiopharmaceutical discovery, toxicology and pre-clinical efficacy research, and this program can serve as a vehicle to advance innovative solutions in these areas.”

Outside of CNRI, CNL is working to set up itself as a global hub in the analysis, improvement and provide of next-generation medical isotopes and radiopharmaceuticals, together with Actinium-225, a uncommon isotope that exhibits nice promise as the foundation for brand spanking new, cutting-edge most cancers therapies. As half of these efforts, CNL lately signed a Memorandum of Understanding with ITM Isotope Technologies Munich SE to discover the improvement and industrial-scale manufacturing of Actinium-225.

To study extra about CNL and its work in well being sciences, please go to For extra info on the CNRI Health Stream, together with submission pointers and particulars, please go to

About CNL
Canadian Nuclear Laboratories is a world chief in nuclear science and expertise, providing distinctive capabilities and options throughout a variety of industries. Actively concerned with industry-driven analysis and improvement in nuclear, transportation, clear expertise, vitality, defence, safety and life sciences, we offer options to hold these sectors aggressive internationally.

With ongoing investments in new services and a targeted mandate, Canadian Nuclear Laboratories is properly positioned for the future. A brand new efficiency customary strengthened with a powerful security tradition underscores each exercise.

For extra info on the full vary of Canadian Nuclear Laboratories providers, please go to or contact [email protected].

CNL Contact:
Patrick Quinn
Director, Corporate Communications
Phone: 1-866-886-2325
Email: [email protected]

A photograph accompanying this announcement is obtainable at


Leave a Reply

Your email address will not be published. Required fields are marked *